{"pmid":32341908,"pmcid":"PMC7182749","title":"Diagnostic and digital solutions to address the COVID-19 pandemic: The need for international collaboration to close the gap.","text":["Diagnostic and digital solutions to address the COVID-19 pandemic: The need for international collaboration to close the gap.","Health Policy Technol","Kyhlstedt, Mattias","Andersson, Sarah Wamala","32341908"],"journal":"Health Policy Technol","authors":["Kyhlstedt, Mattias","Andersson, Sarah Wamala"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341908","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.hlpt.2020.04.010","keywords":["covid-19","diagnostics","digital health"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1666138495054249986,"score":9.490897,"similar":[{"pmid":32340107,"title":"The Use of Digital Health in the Detection and Management of COVID-19.","text":["The Use of Digital Health in the Detection and Management of COVID-19.","Digital health is uniquely positioned to enhance the way we detect and manage infectious diseases. This commentary explores the potential of implementing digital technologies that can be used at different stages of the COVID-19 outbreak, including data-driven disease surveillance, screening, triage, diagnosis, and monitoring. Methods that could potentially reduce the exposure of healthcare providers to the virus are also discussed.","Int J Environ Res Public Health","Alwashmi, Meshari F","32340107"],"abstract":["Digital health is uniquely positioned to enhance the way we detect and manage infectious diseases. This commentary explores the potential of implementing digital technologies that can be used at different stages of the COVID-19 outbreak, including data-driven disease surveillance, screening, triage, diagnosis, and monitoring. Methods that could potentially reduce the exposure of healthcare providers to the virus are also discussed."],"journal":"Int J Environ Res Public Health","authors":["Alwashmi, Meshari F"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340107","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/ijerph17082906","keywords":["covid-19","digital health","infectious disease","mhealth"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1666138495086755841,"score":76.00526},{"pmid":32416956,"title":"Digital Orthopaedics: A Glimpse Into the Future in the Midst of a Pandemic.","text":["Digital Orthopaedics: A Glimpse Into the Future in the Midst of a Pandemic.","BACKGROUND: The response to COVID-19 catalyzed the adoption and integration of digital health tools into the health care delivery model for musculoskeletal patients. The change, suspension, or relaxation of Medicare and federal guidelines enabled the rapid implementation of these technologies. The expansion of payment models for virtual care facilitated its rapid adoption. The authors aim to provide several examples of digital health solutions utilized to manage orthopedic patients during the pandemic and discuss what features of these technologies are likely to continue to provide value to patients and clinicians following its resolution. CONCLUSION: The widespread adoption of new technologies enabling providers to care for patients remotely has the potential to permanently change the expectations of all stakeholders about the way care is provided in orthopedics. The new era of Digital Orthopaedics will see a gradual and nondisruptive integration of technologies that support the patient's journey through the successful management of their musculoskeletal disease.","J Arthroplasty","Bini, Stefano A","Schilling, Peter L","Patel, Shaun P","Kalore, Niraj V","Ast, Michael P","Maratt, Joseph D","Schuett, Dustin J","Lawrie, Charles M","Chung, Christopher C","Steele, G Daxton","32416956"],"abstract":["BACKGROUND: The response to COVID-19 catalyzed the adoption and integration of digital health tools into the health care delivery model for musculoskeletal patients. The change, suspension, or relaxation of Medicare and federal guidelines enabled the rapid implementation of these technologies. The expansion of payment models for virtual care facilitated its rapid adoption. The authors aim to provide several examples of digital health solutions utilized to manage orthopedic patients during the pandemic and discuss what features of these technologies are likely to continue to provide value to patients and clinicians following its resolution. CONCLUSION: The widespread adoption of new technologies enabling providers to care for patients remotely has the potential to permanently change the expectations of all stakeholders about the way care is provided in orthopedics. The new era of Digital Orthopaedics will see a gradual and nondisruptive integration of technologies that support the patient's journey through the successful management of their musculoskeletal disease."],"journal":"J Arthroplasty","authors":["Bini, Stefano A","Schilling, Peter L","Patel, Shaun P","Kalore, Niraj V","Ast, Michael P","Maratt, Joseph D","Schuett, Dustin J","Lawrie, Charles M","Chung, Christopher C","Steele, G Daxton"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416956","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.arth.2020.04.048","keywords":["covid-19","digital health","digital orthopaedics","future","telehealth","virtual visits"],"topics":["Prevention"],"weight":1,"_version_":1667058206862475264,"score":67.80102},{"pmid":32435872,"title":"Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","text":["Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays.","Adv Biochem Eng Biotechnol","Arshavsky-Graham, Sofia","Segal, Ester","32435872"],"abstract":["The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays."],"journal":"Adv Biochem Eng Biotechnol","authors":["Arshavsky-Graham, Sofia","Segal, Ester"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435872","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/10_2020_127","keywords":["centrifugal microfluidics","diagnostics","lab-on-a-chip","microfluidics","paper","point-of-care","smartphone"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393849270272,"score":67.747406},{"pmid":32260471,"title":"In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","text":["In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.","Diagnostics (Basel)","Vashist, Sandeep Kumar","32260471"],"abstract":["There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19."],"journal":"Diagnostics (Basel)","authors":["Vashist, Sandeep Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260471","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/diagnostics10040202","keywords":["covid-19","sars-cov-2","diagnostics","immunoassays","lateral flow immunoassay (lfia)","point-of-care (poc)","real-time reverse transcriptase polymerase chain (rt-pcr)"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491909570561,"score":67.678505},{"pmid":32365567,"title":"Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics.","text":["Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics.","In the last three decades, microfluidics and its applications have been on an exponential rise, including approaches to isolate rare cells and diagnose diseases on the single-cell level. The techniques mentioned herein have already had significant impacts in our lives, from in-the-field diagnosis of disease and parasitic infections, through home fertility tests, to uncovering the interactions between SARS-CoV-2 and their host cells. This review gives an overview of the field in general and the most notable developments of the last five years, in three parts: 1. What can we detect? 2. Which detection technologies are used in which setting? 3. How do these techniques work? Finally, this review discusses potentials, shortfalls, and an outlook on future developments, especially in respect to the funding landscape and the field-application of these chips.","Micromachines (Basel)","Hochstetter, Axel","32365567"],"abstract":["In the last three decades, microfluidics and its applications have been on an exponential rise, including approaches to isolate rare cells and diagnose diseases on the single-cell level. The techniques mentioned herein have already had significant impacts in our lives, from in-the-field diagnosis of disease and parasitic infections, through home fertility tests, to uncovering the interactions between SARS-CoV-2 and their host cells. This review gives an overview of the field in general and the most notable developments of the last five years, in three parts: 1. What can we detect? 2. Which detection technologies are used in which setting? 3. How do these techniques work? Finally, this review discusses potentials, shortfalls, and an outlook on future developments, especially in respect to the funding landscape and the field-application of these chips."],"journal":"Micromachines (Basel)","authors":["Hochstetter, Axel"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32365567","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/mi11050468","keywords":["biomedical engineering","cancer","diagnostics","infectious diseases","microfluidics","parasites","point-of-care","single cell level"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496304152576,"score":66.24921}]}